Earlier diagnosis of invasive fusariosis with Aspergillus serum galactomannan testing

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Nucci, Marcio ^a   Carlesse, Fabianne ^b   Cappellano, Paola ^b   Varon, Andrea G ^a   Seber, Adriana ^b   Garnica, Marcia ^a   Nouér, Simone A ^a   Colombo, Arnaldo L ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CARBOHYDRATE ANTIGEN; GALACTOMANNAN ANTIGEN; UNCLASSIFIED DRUG; VORICONAZOLE;

ADOLESCENT; ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD CULTURE; BRAZIL; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNGUS CULTURE; FUSARIOSIS; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY ANALYZER; INVASIVE FUSARIOSIS; MALE; MEDICAL RECORD REVIEW; PATIENT SELECTION; PREVALENCE; REFERENCE VALUE; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SYSTEMIC MYCOSIS; TREATMENT RESPONSE;

ANTIFUNGAL AGENTS; ASPERGILLUS; BIOLOGICAL MARKERS; BRAZIL; CROSS REACTIONS; EARLY DIAGNOSIS; FUSARIOSIS; HUMANS; KINETICS; MANNANS; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84900324352     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087784     Document Type: Article

References (31)

1. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, et al. (2012) ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 47: 846-854.
2. Maertens J, Verhaegen J, Lagrou K, Van EJ, Boogaerts M (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97: 1604-1610. (Pubitemid 32217224)
3. Nouer SA, Nucci M, Kumar NS, Grazziutti M, Barlogie B, et al. (2011) Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis 53: 671-676.
4. Nucci M, Nouer SA, Grazziutti M, Kumar NS, Barlogie B, et al. (2010) Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis 51: 1273-1280.
5. Chai LY, Kullberg BJ, Johnson EM, Teerenstra S, Khin LW, et al. (2012) Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol 50: 2330-2336.
6. Van D, V, Lewis RJ, Emtiazjoo AM, Allen SD, Wheat LJ, et al. (2012) Cross-reactivity in the Platelia Aspergillus enzyme immunoassay caused by blastomycosis. Med Mycol 50: 396-398.
7. Fekkar A, Brun S, D'Ussel M, Uzunov M, Cracco C, et al. (2009) Serum cross-reactivity with Aspergillus galactomannan and cryptococcal antigen during fatal disseminated Trichosporon dermatis infection. Clin Infect Dis 49: 1457-1458.
8. Cummings JR, Jamison GR, Boudreaux JW, Howles MJ, Walsh TJ, et al. (2007) Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Microbiol Infect Dis 59: 113-115. (Pubitemid 47391183)
9. Giacchino M, Chiapello N, Bezzio S, Fagioli F, Saracco P, et al. (2006) Aspergillus galactomannan enzyme-linked immunosorbent assay cross-reactivity caused by invasive Geotrichum capitatum. J Clin Microbiol 44: 3432-3434. (Pubitemid 44413798)
10. Mikulska M, Furfaro E, Del B, V, Gualandi F, Raiola AM, et al. (2012) Galactomannan testing might be useful for early diagnosis of fusariosis. Diagn Microbiol Infect Dis 72: 367-369.
11. Tortorano AM, Esposto MC, Prigitano A, Grancini A, Ossi C, et al. (2012) Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 50: 1051-1053.
12. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, et al. (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46: 1813-1821.
13. Notermans S, Dufrenne J, Wijnands LM, Engel HW (1988) Human serum antibodies to extracellular polysaccharides (EPS) of moulds. J Med Vet Mycol 26: 41-48.
14. Hope WW, Walsh TJ, Denning DW (2005) Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 5: 609-622. (Pubitemid 41383906)
15. Tanriover MD, Ascioglu S, Altun B, Uzun O (2010) Galactomannan on the stage: prospective evaluation of the applicability in routine practice and surveillance. Mycoses 53: 16-25.
16. Nucci M, Garnica M, Gloria AB, Lehugeur DS, Dias VC, et al. (2012) Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect 19: 745-51.
17. Reinwald M, Hummel M, Kovalevskaya E, Spiess B, Heinz WJ, et al. (2012) Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother 67: 2260-2267.
18. McCulloch E, Ramage G, Rajendran R, Lappin DF, Jones B, et al. (2012) Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis. J Clin Pathol 65: 83-86.
19. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, et al. (2004) Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190: 641-649. (Pubitemid 38982107)
20. Nucci M, Anaissie E (2006) Emerging fungi. Infect Dis Clin North Am 20: 563-579. (Pubitemid 44389926)
21. Nucci M, Anaissie E (2007) Fusarium infections in immunocompromised patients. Clin Microbiol Rev 20: 695-704. (Pubitemid 47623773)
22. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, et al. (2003) Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 98: 315-319. (Pubitemid 36828456)
23. Maertens J, Buve K, Theunissen K, Meersseman W, Verbeken E, et al. (2009) Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 115: 355-362.
24. Mikulska M, Raiola AM, Signori A, Furfaro E, Del B, V, et al.(2013) Screening with serum galactomannan might be associated with better outcome than symptoms-triggered galactomannan testing in allogeneic HSCT recipients with invasive aspergillosis. Clin Infect Dis. cit565 [pii];10.1093/cid/cit565 [doi].
25. Maertens JA, Nucci M, Donnelly JP (2012) The role of antifungal treatment in hematology. Haematologica 97: 325-327.
26. Bergeron A, Porcher R, Menotti J, Poirot JL, Chagnon K, et al. (2012) Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J Clin Microbiol 50: 823-830.
27. Chai LY, Kullberg BJ, Johnson EM, Teerenstra S, Khin LW, et al. (2012) Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol 50: 2330-2336.
28. Koo S, Bryar JM, Baden LR, Marty FM (2010) Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 48: 1255-1260.
29. Maertens J, Buve K, Theunissen K, Meersseman W, Verbeken E, et al. (2009) Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 115: 355-362.
30. Nouer SA, Nucci M, Kumar NS, Grazziutti M, Restrepo A, et al. (2012) Baseline platelet count and creatinine clearance rate predict the outcome of neutropenia-related invasive aspergillosis. Clin Infect Dis 54: e173-e183.
31. Park SH, Choi SM, Lee DG, Choi JH, Kim SH, et al. (2011) Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients. Mycoses 54: 523-530.